

Prescription drug price transparency public hearing agenda

Date/Time: Wednesday, Dec. 16, 2020
10 a.m. to noon

Location: Zoom meeting -

- dcbspage.org/RXDRUGPRICEHEARING2020
- One tap mobile: 253-215-8782
- Reserved for in-office staff – L&I 260

Oregonians are encouraged to submit questions related to drug pricing/hearing topics or submit testimony on drug pricing. Members of the public may sign-up to give testimony in the Zoom chat window.

Moderator panel

Andrew Stolfi – Director, Oregon Department of Consumer and Business Services
Jeremy Vandahey – Director, Health Policy & Analytics, Oregon Health Authority
Representative Rob Nosse (D)
Senator Lee Beyer (D)

AGENDA

Welcome and introductions – 10-10:10

Andrew Stolfi, Director, Department of Consumer and Business Services

Drug Price Transparency Program presentation 10:10-10:30

Numi Lee Griffith, Program Coordinator, Drug Price Transparency Program
Antonio Vargas, Research Analyst, Drug Price Transparency Program

Public comment one – 10:30-10:40

Members of the public are invited to sign up for either this or the second block of time at the end of the program. We may adjust precise timing depending on the level of interest.

Invited panel one – pricing of COVID-19 therapeutics 10:40-11:10

ICER – Sarah Emond
Tobias Read, Oregon State Treasurer
TBD / Donna Steward, Senior Director of State Policy, PhRMA

Invited panel two – State actions on drug prices 11:10-11:30

Colorado – Lauren Reveley, Drug Importation Program Manager

Maryland – Kris Vallecillo, Policy Analyst (Drug Affordability Board)

NASHP – Jennifer Reck (Overview of emerging policy actions)

Invited panel three – Federal landscape on drug pricing 11:30-11:45

Stephanie Kennan, SVP Government Relations, McGuireWoods Consulting LLC (Overview of federal policy environment on drug prices)

Donna Steward, Senior Director of State Policy, PhRMA

Public comment two – 11:45-11:55

Wrap-up

Closing statements from moderator panelists